{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T14:26:25Z","timestamp":1770474385743,"version":"3.49.0"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2003,12,22]],"date-time":"2003-12-22T00:00:00Z","timestamp":1072051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2004,1]]},"abstract":"<jats:title>Abstract:<\/jats:title><jats:p>Except rare instances of allogeneic stem cell transplantation, treatment of idiopathic myelofibrosis (IMF) is only palliative and based on cytostatic treatment (hydroxyurea and anagrelide), androgen therapy, steroids and splenectomy. Thalidomide is an anti\u2010angiogenic and immunmodulatory drug with a wide spectrum of activities, which are not clearly understood. Current data suggest that the action of thalidomide is related to several different mechanisms, including suppression of tumor necrosis factor, effects on basic fibroblast growth factor, vascular endothelial growth factor, interleukins and interferons, downregulation of selected cell surface adhesion molecules, and changes in the lymphocyte subsets.<\/jats:p><jats:p>We administered thalidomide to 16 patients with IMF (15 men, one women) who had transfusion\u2010dependent anemia, thrombocytopenia or symptomatic splenomegaly. Median age was 59\u2003yr (range: 52\u201378). Patients received thalidomide at an escalating dose from 100 to 400\u2003mg\/d (median 300\u2003mg). The drug was discontinued in four patients because of progressive disease (two) or polyneuropathy (two). Other adverse effects were obstipation (10), fatigue (eight) and edema (two). Clinical response has now been observed for a median duration of 9\u2003months (range: 3\u201320). Fifteen patients are evaluable. Anemia improved in six of 10\u2003patients who were anemic. Platelet counts improved in five of seven patients with thrombocytopenia. Splenomegaly regressed in three of 13\u2003patients. Lactate dehydrogenase (LDH) decreased in seven of 12 patients, but increased in four patients. LDH levels were not correlated with clinical response. In summary, thalidomide appears useful in the treatment of IMF.<\/jats:p>","DOI":"10.1046\/j.0902-4441.2003.00188.x","type":"journal-article","created":{"date-parts":[[2003,12,22]],"date-time":"2003-12-22T10:50:16Z","timestamp":1072090216000},"page":"52-57","source":"Crossref","is-referenced-by-count":19,"title":["Thalidomide for the treatment of idiopathic myelofibrosis"],"prefix":"10.1111","volume":"72","author":[{"given":"C.","family":"Strupp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Germing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"K\u00fcndgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"M\u00f6dder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Gattermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,12,22]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.2255"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.3.586"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10076"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02883.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.2252"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0154"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412102"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402330"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190210190"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02918.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03072.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03443.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1385\/MO:19:2:79"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2928"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402596"},{"key":"e_1_2_6_17_2","first-page":"772","article-title":"Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia","volume":"86","author":"Pozzato G","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.12.4007"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004728-199107000-00018"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.171.4.9762973"},{"key":"e_1_2_6_21_2","first-page":"2305","article-title":"Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging\u2010based parameters and a histomorphological approach in correlation with disease outcome","volume":"4","author":"Hawighorst H","year":"1998","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-003-2000-y"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1421"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-20096"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.58.2008.i107"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.9.4082"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.1.210"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.187.11.1885"},{"key":"e_1_2_6_29_2","first-page":"177","article-title":"Immunmodulation by thalidomide: systematic review of the literature and of unpublished observations","volume":"46","author":"Zwingenberger K","year":"1996","journal-title":"J Inflamm"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.0902-4441.2003.00188.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.0902-4441.2003.00188.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.0902-4441.2003.00188.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T12:45:17Z","timestamp":1697201117000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.0902-4441.2003.00188.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12,22]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["10.1046\/j.0902-4441.2003.00188.x"],"URL":"https:\/\/doi.org\/10.1046\/j.0902-4441.2003.00188.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12,22]]}}}